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our study was to investigate the efﬁcacy of cells transplantation
in an experimental animal model by means of autologous mes-
enchymal stem cells, obtained from bone marrow, grown onto a
hyaluronan-based scaffold (Hyaff®-11).
Methods: Rabbit knee joints were subjected to anterior cruci-
ate ligament resection to surgically induce OA. After 8 weeks
necessary for the detection of cartilage surface damage and
proteoglycan loss, mesenchymal stem cells obtained from bone
marrow harvested from the iliac crest and seeded onto Hyaff®-
11 scaffold were put on the chondyle surface and the animals
were sacriﬁced 3 and 6 months after surgery. Cartilage obtained
from animals treated with the scaffold alone or left untreated
was used as control. Morphological, histological and immuno-
histological evaluations were performed on the different tissues.
Real-Time PCR analysis was performed on cartilage tissues to
evaluate the gene expression proﬁles.
Results: OA changes developed in all animals subjected to
ACL resection. The predominant macroscopically observed OA
changes were mild (lateral femoral condyle) or medium (medial
femoral condyle) ulcerations. Statistically signiﬁcant differences
in the quality of the regenerated tissue were found between the
grafts carried out with biomaterial carrying mesenchymal stem
cells compared to the biomaterial alone or controls in particular
at six months.
Conclusions: In conclusion, from our data it is possible to
demonstrate that Hyaff®-11 is a promising scaffold for mes-
enchymal transplantation and should be applicable to humans
for the treatment of early osteoarthritis.
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EFFECT OF LOW-INTENSITY PULSED ULTRASOUND ON
THE MATRIX SYNTHESIS OF SCAFFOLD -FREE
CARTILAGE CULTURE
K. Uenaka, S. Imai, M. Kubo, K. Ando, T. Mimura, N. Okumura,
Y. Matsusue, E. Isoya
Shiga University of Medical Science, Otu,Shiga, Japan
Purpose: The aim of this study is to evaluate the effect of low-
intensity pulsed ultrasound (LIPUS) on the matrix-synthesis of
scaffold-free cartilage culture.
Methods: Chondrocytes are collected from articular cartilage
of Wistar rats. The collected primary chondrocytes (passage
0) were cultured up to subconﬂuent. The cells were then con-
densed to various densities ranging from 105 -107cells/cm2 (P1).
The cells were stimulated by LIPUS for 20 min/day. The mode of
the applied ultrasound is a 200µs burst sine wave of 1.5 MHz
repeating at 1kHz with an intensity of 30mW/cm2. To investi-
gate effect LIPUS stimulation on the matrix-synthesis of the P1
chondrocytes, mRNA expression of type II collagen (col2) and
aggrecan was studied using real-time polymerase chain reaction
(RT-PCR). Synthesis of type II collagen and proteoglycan was
also assessed histochemically.
Results: The chondrocytes prepared at 106 or 107cells/cm2
detached from the culture well to form chondrocyte sheet on
the day 3 of P1 culture. However, the cells prepared at 105
cells/cm2 remained in the monolayer. The expression of col2 and
aggrecan mRNA was signiﬁcantly lower in the cells prepared
at 105 cells/cm2 than that of 106 or 107cells/cm2. No col2 or
aggrecan synthesis was detected histochemically in the cells
prepared at 105 cells/cm2, implicating de-differentiation of these
cells.
The chondrocytes sheet formed via cell condensation at 106 and
107cells/cm2 grew in thickness until the 7th day of P1 culture.
However, the col2 and aggrecan mRNA expression of the cells
prepared at 107cells/cm2 was signiﬁcantly lower on the day 7
than that of 106 cells/cm2. Histological examination revealed that
the cells prepared at 107cells/cm2 did not increase the intensity
of col2 and aggrecan on day7, implicating attenuation of matrix
synthesis.
The chondrocyte sheet formed via cell condensation at 106
cells/cm2 grew in size until the 14th day of P1 culture. However,
the col2 and aggrecan mRNA expression was signiﬁcantly de-
creased on day 14, implicating that the chondrocyte sheet did not
sustain matrix synthesis during the time period between day 7 to
14. However, LIPUS stimulation sustained the expression of col2
and aggrecan mRNA until day 14. The resultant scaffold-free
cartilage was histochemically similar to the articular cartilage.
Conclusions: The chondrocytes prepared at 106 and 107
cells/cm2 developed into chondcrocyte sheet, but only the former
developed into scaffold-free cartilage when stimulated by LIPUS.
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PATELLAR TAPING AND BRACING FOR THE
TREATMENT OF CHRONIC KNEE PAIN: A SYSTEMATIC
REVIEW AND META-ANALYSIS
S.J. Warden1, R.S. Hinman2, M.A. Watson Jr.1, K.G. Avin1,
A.E. Bialocerkowski2, K.M. Crossley2
1Indiana University, Indianapolis, IN; 2University of Melbourne,
Melbourne, Australia
Purpose: Chronic knee pain is a leading cause of disability,
with the most frequent presentations being anterior knee pain
and knee osteoarthritis (OA) in younger (<50 yr) and older
(>50 yr) individuals, respectively. The mainstay of treatment for
chronic knee pain is the management of symptoms with two
frequently used treatments being therapeutic tape and bracing
of the patella. While clinically popular and recommended, the
effectiveness of patellar taping and bracing in managing chronic
knee pain remains debated. This systematic review and meta-
analysis aimed to evaluate the evidence for patellar taping and
bracing in managing chronic knee pain.
Methods: Randomized or quasi-randomized studies assessing
patellar taping or bracing effects on chronic knee pain were
sourced from seven electronic databases (up to November
2006), and assessed using the PEDro scale. Pain scores were
converted to percentages of the maximum possible score and
reported as mm on a 100 mm analogue scale. Weighted mean
differences were determined, and pooled estimates of taping and
bracing effects obtained using random effects models. Hetero-
geneity between trials and publication bias were explored using
sensitivity analyses and funnel plots, respectively.
Results: Of 16 eligible trials, 13 investigated patellar taping or
bracing effects in individuals with anterior knee pain, while three
investigated taping effects in individuals with knee OA. Method-
ological quality of taping studies was signiﬁcantly higher than
bracing studies (4.8±2.1 vs. 2.8±0.8; P<0.05). Tape applied to
exert a medially-directed force on the patella decreased chronic
knee pain compared to no tape and sham tape by 16.1 mm (100
mm scale; 95% CI -22.2 mm to -10.0 mm, P<0.001) and 10.9
mm (-18.4 mm to -3.4 mm, P<0.001), respectively. For anterior
knee pain and OA, medially directed tape compared to no tape
decreased pain by 14.7 mm (-22.8 mm to -6.9 mm, P<0.001) and
20.1 mm (-26.0 mm to -14.3 mm, P<0.001), respectively. There
was disputable evidence from low quality studies for patellar
bracing beneﬁts.
Conclusions: There was evidence that tape applied to exert
a medially-directed force on the patella produces a clinically
meaningful change in chronic knee pain. There was limited
evidence to demonstrate the efﬁcacy of patellar bracing. These
outcomes were limited by the presence of high heterogeneity
between study outcomes and signiﬁcant publication bias, which
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indicate the need for additional high quality studies into patellar
taping and bracing effects on chronic knee pain.
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SPLINT FOR BASE OF THUMB OSTEOARTHRITIS: A 12
MONTH RANDOMIZED CONTROLLED STUDY
F. Rannou1, F. Fayad1, J. Dimet2, Y. Macé1, J. Beaudreuil3,
P. Richette3, M. Revel3, S. Poiraudeau1
1AP-HP, Université Paris 5, Paris, France; 2Centre Hospitalier,
La Roche sur Yon, France; 3AP-HP, Université Paris 7, Paris,
France
Purpose: Splints for base of the thumb osteoarthritis (OA) are
recommended in international guidelines but evidence for their
efﬁcacy in randomized trials are missing. The objective was to
assess the efﬁcacy and acceptability of splints for base of the
thumb OA.
Methods: Study design: Randomized controlled trial
Setting: Two tertiary care hospitals in France
Patients: 109 (94 women) patients with base of thumb car-
pometacarpal joint OA
Intervention: 56 patients received custom-made neoprene splint
and usual care (intervention) and 53 usual care (control)
Outcome measures: Primary outcome was pain assessed on
Visual Analog Scale (VAS, range 0-100) at 12 month follow-up.
Secondary outcome measures were pain at 1 and 6 month,
disability assessed by the Cochin Hand Function Scale (CHFS,
range 0-90) and pinch strength at 1, 6, and 12 month. Intention-
to-treat analyses were performed.
Results: Pain at 12 month follow-up had signiﬁcantly decreased
in both groups (from 45.5±20.0mm to 23.6±22.8mm in inter-
vention group, p= 0.0001, and from 47.7±20.0 to 39.2±24.2,
p=0.02 in control group), and an inter-group difference was ob-
served (-22.1±25.7 in intervention, and -8.8±25.2 in control
group, p=0.006). Pain inter-group difference was also observed
at 6 month but not at 1 month. Disability at 12 month was
not signiﬁcantly decreased in the intervention group (-2.0±12.9,
p=0.19) but was signiﬁcantly increased in the control group
(3.4±11.3, p=0.04), and an inter-group difference was observed
(p=0.03). Pinch strength was not modiﬁed in intervention and
control group. In the intervention group, 86% of patients wore
their splint at least 5 nights a week at 12 month and no adverse
effect was observed.
Conclusions: Our results suggest that splints are useful, safe,
and acceptable for patients with thumb carpometacarpal joint
OA.
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GLUCOSAMINE SULPHATE IN HIP OA, THE GOAL
STUDY: SUBGROUP ANALYSES
R.M. Rozendaal1, B.W. Koes1, G.J. van Osch1,
E.J. Uitterlinden1, E.H. Garling2, A.Z. Ginai1, J.A. Verhaar1,
H. Weinans1, S.M. Bierma-Zeinstra1
1Erasmus Medical Center, Rotterdam, The Netherlands; 2Leiden
University Medical Center, Leiden, The Netherlands
Purpose: The outcome of the goal study, an independent, long-
term, double-blind RCT in primary care patients with hip os-
teoarthritis (OA), was that glucosamine sulphate (GS) did not
have an effect on the symptoms and progression of hip OA over
the period of two years. In the study protocol subgroup analyses
were pre-speciﬁed to assess the effect of GS in subgroups of
patients.
Methods: In the GOAL study we randomly assigned 222 pa-
tients with hip OA to either 1500 mg of oral GS or a placebo
once daily for two years. Randomisation was stratiﬁed for severity
of radiographic OA (Kellgren and Lawrence (KL) = 1 vs. KL ≥
2) and for localisation (localised vs. generalised OA). For these
groups subgroup analyses were pre-speciﬁed. For additional ex-
ploratory analyses patients were also divided into groups based
on baseline level of pain (VAS ≤ 30 vs. VAS > 30).
General practitioners recruited prevalent hip OA patients. Pa-
tients were eligible when they met at least the clinical set of the
ACR criteria for hip OA. One of the exclusion criteria was being
on the waiting list for a total hip arthroplasty (THA).
Primary outcome measures were Western Ontario MacMas-
ter Universities (WOMAC) pain and function subscales over 24
months (0-100, 0 equals no pain), and joint space narrowing
(JSN) over 24 months. The WOMAC data was analysed using
mixed model analyses incorporating the scores from 3-monthly
questionnaires throughout the study, adjusted for possible con-
founders. The data for JSN was analysed using linear regression
analysis.
Results: We did not ﬁnd a signiﬁcant difference between GS
and placebo in any of the subgroups (Table 1). The outcomes for
WOMAC pain were adjusted for gender and BMI.
Table 1. Results per subgroup
Change from baseline (SD) Adjusted difference
(95% CI)Placebo group GS group
WOMAC pain
KL=1 (n = 117) -1.48 (26.0) -4.73 (19.3) -2.62 (-7.87, 2.63)
KL≥2 (n=105) 3.84 (26.8) 3.61 (21.8) 0.58 (-5.53, 6.69)
WOMAC function
KL=1 -1.04 (18.1) -2.62 (19.0) -3.09 (-7.45, 1.27)
KL≥2 5.58 (21.3) 1.94 (19.3) -0.58 (-6.05, 4.90)
JSN
KL=1 0.007 (0.29) -0.089 (0.36) -0.095 (-0.218, 0.029)
KL≥2 -0.136 (0.35) -0.102 (0.26) 0.066 (-0.082, 0.213)
WOMAC pain
localised (n=85) 1.76 (31.2) -1.10 (20.4) 0.99 (-5.89, 7.88)
generalised (n=137) 0.28 (22.8) -1.76 (21.1) -2.64 (-7.43, 2.14)
WOMAC function
localised 1.17 (23.0) -2.23 (20.2) -1.58 (-7.41, 4.24)
generalised 2.44 (17.3) 0.28 (18.3) -2.18 (-6.47, 2.10)
WOMAC pain
VAS ≤ 30 (n=122) 6.13 (23.7) 1.10 (21.0) -2.68 (-7.44, 2.08
VAS > 30 (n=100) -8.02 (28.5) -4.52 (20.1) -0.54 (-6.86, 5.78)
WOMAC function
VAS ≤ 30 4.81 (20.0) 1.09 (20.3) -3.14 (-7.40, 1.12)
VAS > 30 -3.10 (18.6) -3.13 (17.5) 1.56 (-7.27, 4.16)
In the subgroup of patients with KL = 1, the pain score of patients
on GS was better, while in the group with KL ≥ 2 this score was
better for the patients taking placebo. For WOMAC function the
estimates were in favour of placebo in both subgroups.
For subgroup analyses on the outcome for JSN, we found for
the group with KL = 1 that the patients taking placebo had less
JSN. In the group with KL ≥ 2 the patients in the GS group had
less JSN. None of the differences in the subgroups based on
radiographic severity were statistically signiﬁcant.
When we divided patients on the basis of localisation, we found
that in the group of patients with generalised OA, the patients
on GS scored better on pain and function than the patients
on placebo. Of the patients with localised OA, the ones taking
GS scored better on WOMAC function, while the patients taking
placebo scored better on WOMAC pain. The differences seen in
the subgroups based on localisation of OA were not statistically
signiﬁcant.
Finally we divided patients on the basis of their baseline VAS pain
score. In the group scoring lower than or equal to 30, the patients
taking GS had a better score on the WOMAC pain and function.
For the group with a baseline VAS of over 30, the ones on GS
scored better on WOMAC pain, but worse on WOMAC function.
Again, the differences described in the subgroups based on
baseline VAS score were not statistically signiﬁcant.
Conclusions: A once daily dose of 1500 mg of glucosamine
